Winton Group LTD Cel Sci Corp Transaction History

Winton Group LTD

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2019 Nov 08, 2019	SELL	$6.0 - $9.6 $63,462 - $101,539	-10,577 Closed	0 $0
Q2 2019 Jul 08, 2019	BUY	$3.77 - $8.67 $399 - $919	106 Added 1.01%	10,577 $89,000
Q1 2019 May 13, 2019	BUY	$2.58 - $3.54 $27,015 - $37,067	10,471 New	10,471 $37,000

27.1K

150K

Ticker CVM
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,367,500
Market Cap $26.9M
Description
CEL-SCI Corporation engages in the research and development of immunotherapy for the treatment of cancer and infectious diseases. The company's lead investigational immunotherapy is Multikine, which is under phase III clinical trial for the treatment of head and neck cancer. Its Ligand Epitope Antigen Presentation System (LEAPS), a pre-clinical ...

Get notified when there are updates to the investment portfolio of Winton Group LTD, based on Form 13F filings with the SEC.

Stay updated on Winton Group LTD with notifications on news.